Form 8K Silexion Therapeutics
Corp For: 9 November
- Investing.com
Metrics to compare | SLXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.5x | −0.2x | |
PEG Ratio | - | −0.01 | 0.00 | |
Price/Book | 7.6x | 0.0x | 2.6x | |
Price / LTM Sales | - | 3.9x | 2.7x | |
Upside (Analyst Target) | - | 1,347.9% | 69.6% | |
Fair Value Upside | Unlock | 29.0% | 11.7% | Unlock |
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.